ReviewFrontiers in immunology2026
TGFBI in tumors and the tumor immune microenvironment: functional roles, mechanisms, and therapeutic targeting.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TGFBI in tumors, providing a comprehensive theoretical foundation for developing TGFBI-based precision diagnosis and treatment. Transforming growth factor-beta-induced protein (TGFBI) is a secreted extracellular matrix protein involved in various physiological and pathological processes. Its multiple roles in tumorigenesis and the remodeling of the tumor immune microenvironment (TIME) have recently drawn increasing attention. This review systematically compares the dual pro-tumor and tumor-suppressive functions of TGFBI across multiple cancer types and provides a comprehensive analysis of its immunomodulatory roles-particularly its recently identified function as a secreted immune checkpoint bridging extracellular matrix remodeling and immune suppression. By integrating evidence from single-cell and spatial transcriptomic studies, we elucidate the cell-type-specific expression patterns of TGFBI in the tumor microenvironment and propose a tumor-type-specific therapeutic stratification framework for TGFBI-targeted interventions. This review thus fills a critical gap by providing the first systematic integration of TGFBI's context-dependent functions with its translational implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.